CoChat

Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia

Open access
Furukawa, Toshi A, Watanabe, Norio, Churchill, Rachel · 2007 · Cochrane Database of Systematic Reviews
Cited by 195

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Panic disorder can be treated with pharmacotherapy, psychotherapy or in combination, but the relative merits of combined therapy have not been well established. OBJECTIVES: To review evidence concerning short- and long-term advantages and disadvantages of combined psychotherapy plus antidepressant treatment for panic disorder with or without agoraphobia, in comparison with either therapy alone. SEARCH STRATEGY: The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Registers (CCDANCTR-Studies and CCDANCTR-References) were searched on 11/10/2005, together with a complementary search of the Cochrane Central Register of Controlled Trials and MEDLINE, using the keywords antidepressant and panic. A reference search, SciSearch and personal contact with experts were carried out. SELECTION CRITERIA: Two independent review authors identified randomised controlled trials comparing the combined therapy against either of the monotherapies among adult patients with panic disorder with or without agoraphobia. DATA COLLECTION AND ANALYSIS: Two independent review authors extracted data using predefined data formats, including study quality indicators. The primary outcome was relative risk (RR) of "response" i.e. substantial overall improvement from baseline as defined by the original investigators. Secondary outcomes included standardised weighted mean differences in global severity, panic attack frequency, phobic avoidance, general anxiety, depression and social functioning and relative risks of overall dropouts and dropouts due to side effects. MAIN RESULTS: We identified 23 randomised comparisons (representing 21 trials, 1709 patients), 21 of which involved behaviour or cognitive-behaviour therapies. In the acute phase treatment, the combined therapy was superior to antidepressant pharmacotherapy (RR 1.24, 95% confidence interval (CI) 1.02 to 1.52) or psychotherapy (RR 1.17, 95% CI 1.05 to 1.31). The combined therapy produced more dropouts due to side effects than psychotherapy (number needed to harm (NNH) around 26). After the acute phase treatment, as long as the drug was continued, the superiority of the combination over either monotherapy appeared to persist. After termination of the acute phase and continuation treatment, the combined therapy was more effective than pharmacotherapy alone (RR 1.61, 95% CI 1.23 to 2.11) and was as effective as psychotherapy (RR 0.96, 95% CI 0.79 to 1.16). AUTHORS' CONCLUSIONS: Either combined therapy or psychotherapy alone may be chosen as first line treatment for panic disorder with or without agoraphobia, depending on patient preference.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd004364.pub2

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Research works printed but not linked: 119

  1. Azhar, 2000, Comparison of fluvoxamine alone, fluvoxamine and cognitive psychotherapy and psychotherapy alone in the treatment of panic disorder in Kelantan--implications for management by family doctors, Medical Journal of Malaysia, 55, 402
  2. Gorman, 2003, The effect of pharmacotherapist characteristics on treatment outcome in panic disorder, Depression and Anxiety, 17, 88, 10.1002/da.10087 · DOI
  3. Grilo, 1998, Pretreatment patient factors predicting attrition from a multicenter randomized controlled treatment study for panic disorder, Comprehensive Psychiatry, 39, 323, 10.1016/S0010-440X(98)90043-8 · DOI · Paper page
  4. Hofmann, 1998, Effects of panic disorder treatments on personality disorder characteristics, Depression and Anxiety, 8, 14, 10.1002/(SICI)1520-6394(1998)8:1<14::AID-DA3>3.0.CO;2-5 · DOI
  5. Barlow, 2000, Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial, JAMA, 283, 2529, 10.1001/jama.283.19.2529 · DOI · Paper page
  6. Gorman, 2003, The effect of pharmacotherapist characteristics on treatment outcome in panic disorder, Depression and Anxiety, 17, 88, 10.1002/da.10087 · DOI
  7. Grilo, 1998, Pretreatment patient factors predicting attrition from a multicenter randomized controlled treatment study for panic disorder, Comprrehensive Psychiatry, 39, 323, 10.1016/S0010-440X(98)90043-8 · DOI · Paper page
  8. Hofmann, 1998, Pretreatment attrition in a comparative treatment outcome study on panic disorder, American Journal of Psychiatry, 155, 43, 10.1176/ajp.155.1.43 · DOI · Paper page
  9. Hofmann, 1998, Effects of panic disorder treatments on personality disorder characteristics, Depression and Anxiety, 8, 14, 10.1002/(SICI)1520-6394(1998)8:1<14::AID-DA3>3.0.CO;2-5 · DOI
  10. Huppert, 2001, Therapists, therapist variables, and cognitive-behavioral therapy outcome in a multicenter trial for panic disorder, Journal of Consulting and Clinical Psychology, 69, 747, 10.1037/0022-006X.69.5.747 · DOI · Paper page
  11. Barlow, 2000, Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial, JAMA, 283, 2529, 10.1001/jama.283.19.2529 · DOI · Paper page
  12. Gorman, 2003, The effect of pharmacotherapist characteristics on treatment outcome in panic disorder, Depression and Anxiety, 17, 88, 10.1002/da.10087 · DOI
  13. Grilo, 1998, Pretreatment patient factors predicting attrition from a multicenter randomized controlled treatment study for panic disorder, Comprehensive Psychiatry, 39, 323, 10.1016/S0010-440X(98)90043-8 · DOI · Paper page
  14. Hofmann, 1998, Pretreatment attrition in a comparative treatment outcome study on panic disorder, American Journal of Psychiatry, 155, 43, 10.1176/ajp.155.1.43 · DOI · Paper page
  15. Hofmann, 1998, Effects of panic disorder treatments on personality disorder characteristics, Depression and Anxiety, 8, 14, 10.1002/(SICI)1520-6394(1998)8:1<14::AID-DA3>3.0.CO;2-5 · DOI
  16. Huppert, 2001, Therapists, therapist variables, and cognitive-behavioral therapy outcome in a multicenter trial for panic disorder, Journal of Consulting and Clinical Psychology, 69, 747, 10.1037/0022-006X.69.5.747 · DOI · Paper page
  17. Berger, 2004, Personality disorder and social anxiety predict delayed response in drug and behavioral treatment of panic disorder, Journal of Affective Disorders, 80, 75, 10.1016/S0165-0327(03)00043-0 · DOI
  18. Beurs, 1999, Long-term outcome of pharmacological and psychological treatment for panic disorder with agoraphobia: a 2-year naturalistic follow-up, Acta Psychiatrica Scandinavica, 99, 59, 10.1111/j.1600-0447.1999.tb05385.x · DOI · Paper page
  19. Beurs, 1995, Perceived upbringing and its relation to treatment outcome in agoraphobia, Clinical Psychology and Psychotherapy, 2, 78, 10.1002/cpp.5640020203 · DOI
  20. Balkom, 1996, Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia, Journal of Nervous and Mental Disease, 184, 133, 10.1097/00005053-199602000-00015 · DOI
  21. van Balkom AJ de Beurs E van Dyck R Lange A Two-year follow-up after treatment of panic disorder with agoraphobia. 8th European College of Neuropsychopharmacology Congress 8th European College of Neuropsychopharmacology Congress 1995 · doi:10.1016/0924-977x(96)87819-9
  22. Beurs, 1995, Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone, American Journal of Psychiatry, 152, 683, 10.1176/ajp.152.5.683 · DOI · Paper page
  23. Beurs, 1999, Long-term outcome of pharmacological and psychological treatment for panic disorder with agoraphobia: a 2-year naturalistic follow-up, Acta Psychiatrica Scandinavica, 99, 59, 10.1111/j.1600-0447.1999.tb05385.x · DOI · Paper page
  24. Beurs, 1995, Perceived upbringing and its relation to treatment outcome in agoraphobia, Clinical Psychology and Psychotherapy, 2, 78, 10.1002/cpp.5640020203 · DOI
  25. Balkom, 1996, Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia, Journal of Nervous and Mental Disease, 184, 133, 10.1097/00005053-199602000-00015 · DOI
  26. van Balkom AJ de Beurs E van Dyck R Lange A Two-year follow-up after treatment of panic disorder with agoraphobia. 8th European College of Neuropsychopharmacology Congress 8th European College of Neuropsychopharmacology Congress 1995 · doi:10.1016/0924-977x(96)87819-9
  27. Beurs, 1995, Treatment of panic disorder with agoraphobia: comparison of fluvoxamine, placebo, and psychological panic management combined with exposure and of exposure in vivo alone, American Journal of Psychiatry, 152, 683, 10.1176/ajp.152.5.683 · DOI · Paper page
  28. Beurs, 1999, Long-term outcome of pharmacological and psychological treatment for panic disorder with agoraphobia: a 2-year naturalistic follow-up, Acta Psychiatrica Scandinavica, 99, 59, 10.1111/j.1600-0447.1999.tb05385.x · DOI · Paper page
  29. Beurs, 1995, Perceived upbringing and its relation to treatment outcome in agoraphobia, Clinical Psychology and Psychotherapy, 2, 78, 10.1002/cpp.5640020203 · DOI
  30. Balkom, 1996, Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia, Journal of Nervous and Mental Disease, 184, 133, 10.1097/00005053-199602000-00015 · DOI
  31. van Balkom AJ de Beurs E van Dyck R Lange A Two-year follow-up after treatment of panic disorder with agoraphobia. 8th European College of Neuropsychopharmacology Congress 8th European College of Neuropsychopharmacology Congress 1995 · doi:10.1016/0924-977x(96)87819-9
  32. Fahy, 1992, The Galway Study of Panic Disorder. I: Clomipramine and lofepramine in DSM III-R panic disorder: a placebo controlled trial, Journal of Affective Disorders, 25, 63, 10.1016/0165-0327(92)90094-M · DOI
  33. O'Rourke, 1996, The Galway study of panic disorder III: Outcome at 5 to 6 years, British Journal of Psychiatry, 168, 462, 10.1192/bjp.168.4.462 · DOI · Paper page
  34. Johnson, 1995, Clomipramine therapy and behavior therapy with agoraphobic women, Canadian Journal of Psychiatry - Revue Canadienne De Psychiatrie, 40, 192
  35. Loerch, 1999, Randomised placebo-controlled trial of moclobemide, cognitive- behavioural therapy and their combination in panic disorder with agoraphobia, British Journal of Psychiatry, 174, 205, 10.1192/bjp.174.3.205 · DOI · Paper page
  36. Cohen, 1984, Two-year follow-up of agoraphobics after exposure and imipramine, British Journal of Psychiatry, 144, 276, 10.1192/bjp.144.3.276 · DOI · Paper page
  37. Lelliott, 1987, Agoraphobics 5 years after imipramine and exposure. Outcome and predictors, Journal of Nervous and Mental Disease, 175, 599, 10.1097/00005053-198710000-00004 · DOI · Paper page
  38. Marks, 1983, Imipramine and brief therapists-aided exposure in agoraphobics having self-exposure homework, Archives of General Psychiatry, 40, 153, 10.1001/archpsyc.1983.01790020047004 · DOI · Paper page
  39. Mavissakalian, 1983, Pharmacological treatment of agoraphobia: imipramine versus imipramine with programmed practice, British Journal of Psychiatry, 143, 348, 10.1192/bjp.143.4.348 · DOI · Paper page
  40. Mavissakalian, 1993, Combined behavioral-therapy and pharmacotherapy of agoraphobia, Journal of Psychiatric Research, 27, 179, 10.1016/0022-3956(93)90027-Y · doi:10.1016/0022-3956(93)90027-y
  41. Mavissakalian, 1982, Agoraphobia: behavioral and pharmacological treatments, preliminary outcome, and process findings, Psychopharmacology Bulletin, 18, 91
  42. Mavissakalian, 1986, Agoraphobia: relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine, Journal of Clinical Psychiatry, 47, 117
  43. Mavissakalian, 1983, Self-directed in vivo exposure practice in behavioral and pharmacological treatments of agoraphobia, Behavior Therapy, 14, 506, 10.1016/S0005-7894(83)80074-4 · DOI
  44. Mavissakalian, 1986, Two-year follow-up of exposure and imipramine treatment of agoraphobia, American Journal of Psychiatry, 143, 1106, 10.1176/ajp.143.9.1106 · DOI · Paper page
  45. Mavissakalian, 1985, Imipramine in the treatment of agoraphobia: dose-response relationships, American Journal of Psychiatry, 142, 1032, 10.1176/ajp.142.9.1032 · DOI
  46. Mavissakalian, 1993, Combined behavioral-therapy and pharmacotherapy of agoraphobia, Journal of Psychiatric Research, 27, 179, 10.1016/0022-3956(93)90027-Y · doi:10.1016/0022-3956(93)90027-y
  47. Mavissakalian, 1982, Agoraphobia: behavioral and pharmacological treatments, preliminary outcome, and process findings, Psychopharmacology Bulletin, 18, 91
  48. Mavissakalian, 1986, Agoraphobia: relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine, Journal of Clinial Psychiatry, 47, 117
  49. Mavissakalian, 1983, Self-directed in vivo exposure practice in behavioral and pharmacological treatments of agoraphobia, Behavior Therapy, 14, 506, 10.1016/S0005-7894(83)80074-4 · DOI
  50. Mavissakalian, 1986, Two-year follow-up of exposure and imipramine treatment of agoraphobia, American Journal of Psychiatry, 143, 1106, 10.1176/ajp.143.9.1106 · DOI · Paper page
  51. Mavissakalian, 1985, Imipramine in the treatment of agoraphobia: dose-response relationships, American Journal of Psychiatry, 142, 1032, 10.1176/ajp.142.9.1032 · DOI
  52. Sharp, 1999, Predicting treatment outcome for panic disorder and agoraphobia in primary care, Clinical Psychology and Psychotherapy, 6, 336, 10.1002/(SICI)1099-0879(199911)6:5<336::AID-CPP205>3.0.CO;2-H · DOI
  53. Sharp, 1998, Psychologist, patient, and general practitioneer ratings of outcome of pharmacological and psychological treatments for panic disorder and agoraphobia in primary care, Behavioural and Cognitive Psychotherapy, 26, 13, 10.1017/S1352465898000034 · DOI
  54. Sharp, 1997, Treatment-outcome research in panic disorder: Dilemmas in reconciling the demands of pharmacological and psychological methodologies, Journal of Psychopharmacology, 11, 373, 10.1177/026988119701100415 · DOI
  55. Sharp, 1997, Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care, British Journal of General Practice, 47, 150
  56. Sharp, 1996, Fluvoxamine, placebo and cognitive behaviour therapy used alone and in combination in the treatment of ppanic disorder and agoraphobia, Journal of Anxiety Disorders, 10, 219, 10.1016/0887-6185(96)00008-4 · DOI
  57. Sharp, 1999, Predicting treatment outcome for panic disorder and agoraphobia in primary care, Clinical Psychology and Psychotherapy, 6, 336, 10.1002/(SICI)1099-0879(199911)6:5<336::AID-CPP205>3.0.CO;2-H · DOI
  58. Sharp, 1998, Psychologist, patient, and general practitioneer ratings of outcome of pharmacological and psychological treatments for panic disorder and agoraphobia in primary care, Behavioural and Cognitive Psychotherapy, 26, 13, 10.1017/S1352465898000034 · DOI
  59. Sharp, 1997, Treatment-outcome research in panic disorder: Dilemmas in reconciling the demands of pharmacological and psychological methodologies, Journal of Psychopharmacology, 11, 373, 10.1177/026988119701100415 · DOI
  60. Sharp, 1997, Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care, British Journal of General Practice, 47, 150
  61. Sharp, 1996, Fluvoxamine, placebo and cognitive behaviour therapy used alone and in combination in the treatment of ppanic disorder and agoraphobia, Journal of Anxiety Disorders, 10, 219, 10.1016/0887-6185(96)00008-4 · DOI
  62. Sharp, 1999, Predicting treatment outcome for panic disorder and agoraphobia in primary care, Clinical Psychology and Psychotherapy, 6, 336, 10.1002/(SICI)1099-0879(199911)6:5<336::AID-CPP205>3.0.CO;2-H · DOI
  63. Sharp, 1998, Psychologist, patient, and general practitioneer ratings of outcome of pharmacological and psychological treatments for panic disorder and agoraphobia in primary care, Behavioural and Cognitive Psychotherapy, 26, 13, 10.1017/S1352465898000034 · DOI
  64. Sharp, 1997, Treatment-outcome research in panic disorder: Dilemmas in reconciling the demands of pharmacological and psychological methodologies, Journal of Psychopharmacology, 11, 373, 10.1177/026988119701100415 · DOI
  65. Sharp, 1997, Global measures of outcome in a controlled comparison of pharmacological and psychological treatment of panic disorder and agoraphobia in primary care, British Journal of General Practice, 47, 150
  66. Sharp, 1996, Fluvoxamine, placebo and cognitive behaviour therapy used alone and in combination in the treatment of ppanic disorder and agoraphobia, Journal of Anxiety Disorders, 10, 219, 10.1016/0887-6185(96)00008-4 · DOI
  67. Sheehan, 1980, Treatment of endogenous anxiety with phobic, hysterical, and hypochondriachal symptoms, Archives of General Psychiatry, 37, 51, 10.1001/archpsyc.1980.01780140053006 · DOI · Paper page
  68. Sheehan, 1980, Treatment of endogenous anxiety with phobic, hysterical, and hypochondriachal symptoms, Archives of General Psychiatry, 37, 51, 10.1001/archpsyc.1980.01780140053006 · DOI · Paper page
  69. Spinhoven, 1996, Panic management, trazodone and a combination of both in the treatment of panic disorder, Clinical Psychology and Psychotherapy, 3, 86, 10.1002/(SICI)1099-0879(199606)3:2<86::AID-CPP91>3.0.CO;2-3 · DOI
  70. Stein, 2000, Do selective serotonin re-uptake inhibitors enhance the efficacy of very brief cognitive behavioral therapy for panic disorder? A pilot study, Psychiatry Research, 94, 191, 10.1016/S0165-1781(00)00154-2 · DOI
  71. Roth, 1988, Autonomic changes after treatment of agoraphobia with panic attacks, Psychiatry Research, 24, 95, 10.1016/0165-1781(88)90145-X · DOI
  72. Telch, 1985, Combined pharmacological and behavioral treatment for agoraphobia, Behavior Research and Therapy, 23, 325, 10.1016/0005-7967(85)90011-7 · DOI · Paper page
  73. Dahl AA Wiborg IM Pharmacotherapy and brief dynamic psychotherapy of panic disorder 9th European College of Neuropsychopharmacology Congress Amsterdam, The Netherlands 1996 · doi:10.1016/0924-977x(96)83138-5
  74. Wiborg, 1996, Does brief dynamic psychotherapy reduce the relapse rate of panic disorder?, Archives of General Psychiatry, 53, 689, 10.1001/archpsyc.1996.01830080041008 · DOI · Paper page
  75. Zitrin, 1983, Differential treatment of phobias: Use of imipramine for panic attacks, Journal of Behavior Therapy and Experimental Psychiatry, 14, 11, 10.1016/0005-7916(83)90006-X · DOI
  76. Zitrin, 1980, Treatment of agoraphobia with group exposure in vivo and imipramine, Archives of General Psychiatry, 37, 63, 10.1001/archpsyc.1980.01780140065007 · DOI · Paper page
  77. Klein, 1987, Panic and avoidance in agoraphobia. Application of path analysis to treatment studies, Archives of General Psychiatry, 44, 377, 10.1001/archpsyc.1987.01800160093011 · DOI · Paper page
  78. Klein, 1983, Treatment of phobias. II. Behavior therapy and supportive psychotherapy: are there any specific ingredients?, Archives of General Psychiatry, 40, 139, 10.1001/archpsyc.1983.01790020033003 · DOI · Paper page
  79. Lipsitz, 1999, Specific phobia 10-16 years after treatment, Depression and Anxiety, 10, 105, 10.1002/(SICI)1520-6394(1999)10:3<105::AID-DA3>3.0.CO;2-X · doi:10.1002/(sici)1520-6394(1999)10:3<105::aid-da3>3.0.co;2-x
  80. Zitrin, 1983, Differential treatment of phobias: Use of imipramine for panic attacks, Journal of Behavior Therapy and Experimental Psychiatry, 14, 11, 10.1016/0005-7916(83)90006-X · DOI
  81. Zitrin, 1976, Comparison of short-term treatment regimens in phobic patients: a preliminary report, 233
  82. Zitrin, 1978, Behavior therapy, supportive psychotherapy, imipramine, and phobias, Archives of General Psychiatry, 35, 307, 10.1001/archpsyc.1978.01770270057005 · DOI · Paper page
  83. Zitrin, 1983, Treatment of phobias. I. Comparison of imipramine hydrochloride and placebo, Archives of General Psychiatry, 40, 125, 10.1001/archpsyc.1983.01790020019002 · DOI · Paper page
  84. Zitrin, 1981, Differentiation of panic anxiety from anticipatory anxiety and avoidance behavior
  85. Vigano C Bielli A Carozzi A Divino T Pagliarulo E Ba G Panic disorder: A two-year follow-up of an integrated treatment approach. Italian Journal of Psychopathology
  86. Chambless, 1982, Exposure and communications training in the treatment of agoraphobia, Behavior Research and Therapy, 20, 219, 10.1016/0005-7967(82)90140-1 · DOI
  87. Chambless, 1979, Flooding with Brevital in the treatment of agoraphobia: countereffective?, Behavior Research and Therapy, 17, 243, 10.1016/0005-7967(79)90039-1 · DOI
  88. Cox, 1988, Different rates of improvement of different symptoms in combined pharmacological and behavioral treatment of agoraphobia, Journal of Behavior Therapy and Experimental Psychiatry, 19, 119, 10.1016/0005-7916(88)90025-0 · DOI
  89. Lipsedge, 1973, The management of severe agoraphobia: a comparison of ipronizaid and systematic desensitization, Psychopharmacologia, 32, 67, 10.1007/BF00421708 · doi:10.1007/bf00421708
  90. Solyom, 1981, Phenelzine and exposure in the treatment of phobias, Biological Psychiatry, 16, 239
  91. American Psychiatric Association, 1998, Practice guideline for the treatment of patients with panic disorder, American Journal of Psychiatry, 155 Supplement, 1
  92. Bucher, 1997, The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials, Journal of Clinical Epidemiology, 50, 683, 10.1016/S0895-4356(97)00049-8 · DOI · Paper page
  93. Burns, 1986, Agoraphobia 8 years after behavioral treatment: a follow-up study with interview, self-report, and behavioral data, Behavior Therapy, 17, 580, 10.1016/S0005-7894(86)80096-X · DOI
  94. Carlbring, 2002, 12-month prevalence of panic disorder with or without agoraphobia in the Swedish general population, Social Psychiatry and Psychiatric Epidemiology, 37, 207, 10.1007/s00127-002-0542-y · DOI
  95. Calrk, 1990, Surreptitious drug use by patients in a panic disorder study, American Journal of Psychiatry, 147, 507, 10.1176/ajp.147.4.507 · DOI · Paper page
  96. Clum, 1993, A meta-analysis of treatments for panic disorder, Journal of Consulting and Clinical Psychology, 61, 317, 10.1037/0022-006X.61.2.317 · DOI · Paper page
  97. Coldiz, 1989, How study design affects outcomes in comparisons of therapy. I: medical, Statistics in Medicine, 9, 441, 10.1002/sim.4780080408 · DOI · Paper page
  98. Goisman, 1995, DSM-IV and the disappearnace of agoraphobia without history of panic disorder: new data on a controversial diagnosis, American Journal of Psychiatry, 152, 1438, 10.1176/ajp.152.10.1438 · DOI · Paper page
  99. Higgins, 2003, Measuring inconsistency in meta-analyses, BMJ, 327, 557, 10.1136/bmj.327.7414.557 · DOI · Paper page
  100. Hollon, 1981, Placebo-psychotherapy combinations: inappropriate representations of psychotherapy in drug-psychotherapy comparative trials, Psychological Bulletin, 90, 467, 10.1037/0033-2909.90.3.467 · DOI
  101. Klein, 2000, Flawed meta-analyses comparing psychotherapy with pharmacotherapy, American Journal of Psychiatry, 157, 1204, 10.1176/appi.ajp.157.8.1204 · DOI · Paper page
  102. Mattick, 1990, Treatment of panic and agoraphobia: an integrative review, Journal of Nervous and Mental Disease, 178, 567, 10.1097/00005053-199009000-00003 · DOI · Paper page
  103. Mavissakalian, 1993, Combined behavioral therapy and pharmacotherapy of agoraphobia, Journal of Psychiatric Research, 27 Suppl 1, 179, 10.1016/0022-3956(93)90027-Y · doi:10.1016/0022-3956(93)90027-y
  104. Mavissakalian, 2002, Duration of imipramine therapy and relapse in panic disorder with agoraphobia, Journal of Clinical Psychopharmacology, 22, 294, 10.1097/00004714-200206000-00010 · DOI · Paper page
  105. Nathan, 2002, A Guide to Treatments that Work
  106. Otto, 1996, Maintenance of remission following cognitive behavior therapy for panic disorder: possible deleterious effects of concurrent medication treatment, Behavior Therapy, 27, 473, 10.1016/S0005-7894(96)80028-1 · DOI
  107. Otto, 2000, Empirically supported treatments for panic disorder: costs, benefits, and stepped care, Journal of Consulting and Clinical Psychology, 68, 556, 10.1037/0022-006X.68.4.556 · doi:10.1037/0022-006x.68.4.556 · Paper page
  108. Pollack, 2003, WCA recommendations for the long-term treatment of panic disorder, CNS Spectrums, 8, 17, 10.1017/S109285290000691X · DOI · Paper page
  109. Schmidt, 1999, Panic disorder: cognitive behavioral and pharmacological treatment strategies, Journal of Clinical Psychology in Medical Settings, 6, 89, 10.1023/A:1026207414971 · DOI
  110. Schmidt, 2001, Combined treatments for phobic anxiety disorders, 81, 10.1037/10415-004 · doi:10.1037/10415-004
  111. Simon, 2002, Longitudinal outcome with pharmacotherapy in a naturalistic study of panic disorder, Journal of Affective Disorders, 69, 201, 10.1016/S0165-0327(01)00359-7 · DOI
  112. Song, 2003, Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses, BMJ, 326, 472, 10.1136/bmj.326.7387.472 · DOI · Paper page
  113. Taylor, 2000, Understanding and Treating Panic Disorder
  114. Telch, 1994, A. Combined pharmacological and psychological tretment of panic disorder: Current status and future directions., 177
  115. Toni, 2000, A prospective naturalistic study of 326 panic-agoraphobic patients treated with antidepressants, Pharmacopsychiatry, 33, 121, 10.1055/s-2000-11221 · DOI · Paper page
  116. Balkom, 1996, Long-term benzodiazepine use is associated with smaller treatment gain in panic disorder with agoraphobia, Journal of Nervous and Mental Disease, 184, 133, 10.1097/00005053-199602000-00015 · DOI
  117. Watanabe, 2005, Combined psychotherapy plus benzodiazepines for panic disorder with or without agoraphobia [Protocol], Cochrane Database of Systematic Reviews, 10.1002/14651858.CD005335 · DOI
  118. Weissman, 1997, The cross-national epidemiology of panic disorder, Archives of General Psychiatry, 54, 305, 10.1001/archpsyc.1997.01830160021003 · DOI · Paper page
  119. Westra, 1998, Cognitive behavioural therapy and pharmacotherapy: complementary or contradictory approaches to the treatment of anxiety?, Clinical Psychology Review, 18, 307, 10.1016/S0272-7358(97)00084-6 · DOI

Cited by

Metadata

Authors
Furukawa, T. A., Watanabe, N., & Churchill, R.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2007-01-24
Volume
2010
Issue
1
Pages
CD004364-CD004364
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W1821129526
Cited by
195
References
23
FWCI
12.93
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.